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While analysing the E6 gene of HPV16 by DNA sequencing, it
was observed that both prototype and variant HPV16 showed an
almost equal prevalence in cervical intra-epithelial neoplasia III
(CIN III), whereas variant HPV16 displayed a marked predomi-
nance in invasive carcinoma of Swedish women (Zehbe et al,
1998). Not all these HPV16 E6 variants were concordant, but the
majority contained a common missense point mutation in base 350
T to G corresponding to a L83V shift in the E6 oncoprotein. It was
therefore assumed that a point mutation in base 350 of E6 signifies
progression of CIN III to invasive carcinoma.
The amino-acid 83 (L) of prototype HPV 16 E6 oncoprotein is
located centrally between the two internal Zn-binding motifs,
which is important for the E6 protein stability (Barbosa et al,
1989). It is surrounded by three conserved amino-acids, S-L-Y-G,
identical in the genital high-risk oncogenic HPV types but
differing in the benign HPV types 6 and 11 (showing AGYA and
AAYA, respectively). Accordingly, the S-L/V-Y-G in E6 of genital
HPV types may be a site affecting the transforming ability of the
virus.
In the present investigation, a collection of invasive cervical
adenocarcinomas infected with HPV16 was analysed for the pres-
ence of a point mutation in codon 83 of the E6 gene, by a novel,
rapid, PCR-based method (Alemi et al, 1999). It was observed that
the HPV16 E6 variant was more predominant in the invasive
squamous lesions than in the adenocarcinomas.
MATERIAL AND METHODS
Tissues
From all Departments of Pathology in Sweden, histopathologi-
cally diagnosed carcinomas are collected in a national database
(The Cancer Registry of the National Board of Health and Welfare
in Sweden), where each specimen is given an individual
topographic and diagnostic code. A total series of 131 cervical
adenocarcinomas were collected from the database. Among them,
28 cases of HPV16 positive adenocarcinomas were identified.
Tumours showing areas with squamous differentiation (adeno-
squamous carcinomas) or without obvious invasion of the stroma
were excluded before the HPV testing. Further, 103 HCIN and 31
invasive cervical squamous carcinomas, with a positive HPV16
reaction, were randomly collected from the local database at the
Department of Pathology in Uppsala. A subpopulation of the squa-
mous lesions has been described before (Zehbe et al, 1998).
HPV-testing
The HPV tests on the specimens had been performed as described
earlier (Zehbe et al, 1996; Zehbe and Wilander, 1997). Briefly, the
analyses were performed on extracted DNA (Lungu et al, 1992)
obtained from sections of the paraffin blocks of which a preceding
section had been used for morphological diagnosis. In a first
sequence, the availability of tissue DNA for PCR amplification
was examined by performing a b-globin test (Saiki et al, 1985).
Secondly, the extracted DNA was analysed with the SHARP
Signal System (Digene Diagnostics, Beltsville, MD) (Manos et al,
1989; Zehbe and Wilander, 1997) and specimens showing HPV of
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L1 region was amplified with GP5+/GP6+ primers and the
amplicon products were HPV-typed by single-strand conforma-
tional polymorphism (SSCP). The method has been described in
detail previously (De Roda Husman et al, 1995; Zehbe et al, 1996).
The E6 gene of HPV16 positive biopsies was amplified by a
primer pair constructed (DNA Technology A/S, Aarhus,
Denmark) from the prototype HPV16 E6 sequence (HPV
Database, Mail Stop K710, Los Alamos National Laboratory, Los
Alamos, NM 87545, USA). The size of the amplicon was 176 base
pairs. The PCR product was run on a SSCP gel and a poly-
morphism of E6 codon 83 was identified after silver staining by
discrepant band pattern of the two sequence variants. The method
has been described in detail before (Alemi et al, 1999). The primer
pairs used for the HPV analyses are specified in Table 1.
HPV DNA sequence analyses
In 20 cases the amplicons were recorded by DNA sequencing in
order to ensure the stability of the PCR-SSCP method for visual-
ization of the E6 codon 83 point mutation. Fluorescence-based
dideoxy terminator cycle sequencing was performed using a Taq
polymerase-based kit (Applied Biosystems Inc., Foster City, USA)
according to the manufacturer’s instructions and an automated
DNA sequencer (Model 310, Applied Biosystems Inc.) The
sequences of both sense and antisense strands of the PCR products
were analysed.
Statistical analysis
Exact two sided Pearson c2 was utilized for the statistical analysis.
RESULTS
Morphology
All adenocarcinomas were of papillary or glandular type and
without any squamous component. From the original collection of
131 pure adenocarcinomas, 17 were considered as in situ tumours
and excluded. Of the remaining 114 tumours 71% were HPV posi-
tive mostly with type 18 (52%) and HPV16 was present in 28 (25%)
of the tumours. The HPV 16 positive invasive squamous carcinomas
of the cervix were of both keratinizing and non-keratinizing type.
HPV16 E6 analysis
All HPV16 variants possessed the nucleotide 350 T to G transition
corresponding to a L83V shift in the E6 oncogene. No other muta-
tions within the amplified E6 segment were observed in any of the
variant HPV16 cases using primers FP and RP (Figure 1).
In the HCIN lesions 62 of 103 cases (60%) contained the proto-
type sequence, whereas in the invasive squamous carcinomas only
6 of 31 (19%) tumours showed the prototype HPV16 E6.
In the invasive cervical adenocarcinomas 13 of 28 (46%)
contained the prototype HPV16 E6 DNA sequence, whereas the
remaining 15 (54%) tumours showed HPV16 variant E6 L83V.
The strong predominance of HPV16 variant E6 seen in squamous
carcinomas was not observed in the adenocarcinomas.
Women with HPV16 positive adenocarcinomas had a mean age
of 47 years. The mean age of women with HPV 16 prototype E6
tumours was 49 years and for those women with HPV16 variant
E6, 46 years. This difference was not statistically significant.
HPV DNA sequence analyses
A complete correlation was observed between results obtained
with the rapid PCR-SSCP method for studying E6 codon 83 poly-
morphism and the HPV 16 E6 DNA sequence analysis. All cases
showing a double band pattern on the polyacrylamide contained a
point mutation at base 350 T to G, and cases displaying a single
band pattern contained a prototype HPV 16 E6 DNA sequence.
Statistical analysis
The different distribution of prototype and variant HPV 16 E6 in
HCIN and invasive squamous carcinoma of the cervix was highly
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Figure 1 Illustration of mid-portion of the HPV E6 gene. Codons 66 and
106 represent the inner Cys residue of Zn-binding domains and codon 83 the
position of the mutated amino-acid (L83V). The forward primer (FP) covers a
relatively rare mutation in codon 78, and reverse primer (RP)





Figure 2 PCR-SSCP (left panel) and nucleotide sequence analysis (right
panel) of the E6 gene PCR products from an HPV 16. (A) Prototype HPV 16
displays a single SSCP band pattern, whereas variant (B) HPV 16 E6
produces a double (aberrant) SSCP band pattern (arrows). The sequences
of prototype and variant were confirmed by non-radioactive nucleotide
sequence analysis. The point mutation (vertical arrow) was found in codon
83: T to G transition causing substitution of leucine for valinesignificant P < 0.001, whereas the difference between HCIN and
adenocarcinoma of the cervix was not significant P = 0.604.
DISCUSSION
In a previous study, HPV16-positive HCIN and invasive cervical
carcinoma were compared with respect to their DNA sequence in
the transforming E6 gene. It was found that prototype HPV16
occurred in 56% of HCIN but in only 6% of the invasive carci-
nomas. By contrast, variant HPV was identified in 44% of HCIN
and in 94% of the carcinomas. Regarding variant HPV16 E6, most
of the cases displayed a common mutation T to G in nucleotide
350, corresponding to an L to V shift in amino-acid number 83 of
the E6 oncoprotein (Zehbe et al, 1998). Since most HCIN lesions
are considered not to progress to invasive carcinoma, the L83V
mutation may signify HPV16-infected women in Sweden with a
high risk of developing cervical carcinoma (Gustafsson and
Adami, 1989; Östör, 1993; Moreni et al, 1995; Zehbe et al, 1998).
This suggestion is in agreement with the observation of
Londesborough et al, (1996) that the proportion of different HPV
16 genotypes varied in LCIN and HCIN lesions. They found a
correlation between the codon 83 mutation T to G in the HPV16
E6 gene a progression of the CIN lesion.
The amino-acid 83 of the E6 oncoprotein is surrounded by
highly conserved amino-acids S-L83V-YG common in all the
high-risk anogenital HPV types, but differing in the benign
anogenital HPV types. For that reason it is conceivable that the
SLYG and SVYG motifs denote a region with a distinct biological
activity (Londesborough et al, 1996; Zehbe et al, 1998). The E6
protein of oncogenic HPV types has a transforming capacity. This
property is likely to be affected by single amino-acid alterations at
functional sites.
HPV 18 is considered as a virus type with a most aggressive
behaviour. This proposal is mainly based on increased virus preva-
lence in invasive carcinoma in comparison with pre-invasive
lesions. Kurman et al (1988) found HPV 18 in only 3% of CIN
compared with 22% in invasive carcinoma. The codons 82–84 of
E6 in prototype HPV 18 and variant HPV 16 are identical and both
display an increased prevalence during progression to invasive
carcinoma.
There is obvious evidence that the genital oncogenic HPV types
are governed by some kind of local tropism. HPV16 has been
shown to be the predominant virus type in cervical and vulvar
squamous carcinomas (Hording et al, 1996; Dargent 1997; Zehbe
et al, 1997; van Burden et al, 1998; Walboomers et al, 1999). HPV
is present in most but not all cervical adenocarcinomas. In these
tumours HPV18 is most prevalent followed by HPV 16 (Zur
Hausen, 1991; Gross and Barasso, 1997) Further, our study shows
the HPV 16 E6 variant L83V was considerably more predominant
in the squamous carcinomas than in the adenocarcinomas. This
may reflect some kind of difference in the mechanism of malig-
nant transformation between adencarcinomas and squamous
carcinomas in the cervix.
A combination of organized and opportunistic screening has
reduced the incidence of squamous carcinoma substantially during
the last decades, whereas the incidence of adenocarcinomas during
the same time period has increased (Bergström et al, 1999)
Epidemiological and molecular biological studies have shown that
infection with high-risk HPV is the most important aetiological
agent in the pathogenesis of cervical cancer (Bosch et al, 1995).
Against this background a new screening strategy for cervical
cancer has been presented in which HPV testing is combined with
cytological examinations (Walboomers, 1999). Based on these
conclusions it is of importance to increase our knowledge of the
malignant potential of the individual HPV types and their variants
and the action of various HPVs on different histological types of
cervical cancer. It is possible that HPV-testing is especially impor-
tant to keep back the increasing incidence of cervical adeno-
carcinoma.
It is emphasized, that the prevalence of oncogenic HPV types
and variants, as well as the genomic background of the female
population vary in different geographic areas (Bosch et al, 1995;
Zehbe et al, 1998). Observations made in the Swedish female
population may for that reason have a different impact in other
countries (Zehbe and Tommasino, 1999).
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Table 1 Primer pairs used for PCR
Primer Sequence 5¢–3¢ Gene Length Product
pair position (bp) size (bp)
b-globin/PCO4 CAACTTCATCCACGTTCACC 54–73 20 268
b-globin/GH20 GAAGAGCCAAGGACAGGTAC 195–176 20
HPV/MY09 CGTCCMARRGGAWACTGATCa L1 (HPV6) 20 398
HPV/MY11b GCMCAGGGWCATAAYAATGGa 20
HPV/GP5+ TTTGTTACTGTGGTAGATACTAC L1 (HPV16) 23 141
HPV/GP6+ GAAAAATAAACTGTAAATCATATTC L1 (HPV16) 25
HPV16 CTAAAATTAGTGAGTATAGACATTA E6 25 176
HPV16 CCTTATATTATGGAATCTTTGC E6 22
HPV, Human papillomavirus. aDegenerate code, M = A + C; R = A + G; W = A + T; X = G + C. bBiotinylated at
its 5¢ end.
Table 2 Distribution of prototype and variant (L83V) HPV 16 E6 in cervical
preinvasive (HCIN) lesions, and invasive squamous carcinomas and
adenocarcinomas
HPV16 HPV16
Histological types prototype E6 variant E6
HCINa 62/103 (60%) 41/103 (40%)b
Squamous carcinomaa 6/31 (19%) 25/31 (81%)
Adenocarcinoma 13/28 (46%) 15/28 (54%)
aA subpopulation of the HCIN and squamous carcinomas has been described
before (Zehbe et al., 1998). bThe difference between HCIN and invasive
carcinoma was statistically significant P < 0.001, whereas the difference
between HCIN and invasive adenocarcinoma was not statistically significant
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